Skip to content

Donald E. Mager

2 papers in the library · 140 citations · publishing 2012-2016

Papers

Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment‐resistant bipolar depression

British Journal of Clinical Pharmacology February 1, 2012 Xiaochen Zhao, Swarajya Lakshmi Vattem Venkata, Ruin Moaddel et al. 136 citations

Ketamine is metabolized into several compounds, and this study shows that norketamine is not the main metabolite circulating in the blood after a single 40-minute infusion of 0.5 mg/kg ketamine in patients with treatment-resistant bipolar depression. Instead, dehydronorketamine was the major metabolite in four out of nine patients, norketamine in three, and hydroxynorketamine in two. Large inter-patient variation in metabolite levels was observed. The findings suggest that future research on ketamine's effects should measure these downstream metabolites.

Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice

Acta Pharmaceutica Sinica B August 6, 2016 Xi-Ling Jiang, Hong-Wu Shen, Donald E. Mager et al. 4 citations

A new computer model describes how the drug harmaline, which inhibits the enzyme monoamine oxidase A, alters body temperature in mice when combined with the serotonin receptor agonist 5-MeO-DMT. Harmaline causes hypothermia by activating 5-HT1A receptors, while 5-MeO-DMT triggers hyperthermia by stimulating 5-HT2A receptors. The model successfully separates drug-induced fever from stress-induced fever caused by handling and injection. When harmaline is given alongside 5-MeO-DMT, the concentration of 5-MeO-DMT needed to produce hyperthermia drops fourfold, showing a quantitative interaction. Dangerous overheating from toxic doses is linked to increased harmaline exposure, not 5-MeO-DMT. This framework may help predict how serotonergic drugs and stress affect thermoregulation.